ELSEVIER
DOYMA

Revisión

Sarcopenia: implications of physical exercise in its pathophysiology, prevention and treatment

J. de D. Beas-Jiménez [a], G. López-Lluch [b], I. Sánchez-Martínez [a], A. Muro-Jiménez [c], E. Rodríguez-Bies [b] and P. Navas [b]

[a] *Andalusian Center of Sports Medicine. Counseling of Tourism, Commerce and Sport. Junta de Andalucía. Sevilla. Spain.*
[b] *Andalusian Center of Developmental Biology. Pablo de Olavide University. CSIC. Department of Phisiology, Anatomy and Cell Biology. CIBERER. Carlos III Institute. Seville. Spain.*
[c] *Blood Transfusion Center of Jaén. Counseling of Health. Junta de Andalucía. Jaén. Spain.*

ABSTRACT

Sarcopenia is known as a progressive muscle wasting produced as years accumulate and characterized by a progressive loss of muscle mass and strength, increase of muscle fat and progressive decline of functional capacity. This process produces important and severe effects on quality of life in elderly people since sarcopenia is the most frequent cause of discapacity, dependency and increase or morbi-mortality. In the present review we analyze the different etiological factors and the prevention and treatment strategies against sarcopenia. One of the main strategies is the strength training that, added to an adequate nutrition, plays a primordial role in prevention and progression of sarcopenia.

© 2011 Revista Andaluza de Medicina del Deporte.

RESUMEN

Sarcopenia: implicaciones del ejercicio físico en su fisiopatología, prevención y tratamiento

Se conoce como sarcopenia al progresivo deterioro muscular que se produce con el paso de los años y que se caracteriza por una pérdida progresiva de fuerza y masa musculares, aumento de la grasa muscular y el deterioro progresivo de la capacidad funcional. Este proceso tiene importantes repercusiones en la calidad de vida de las personas mayores, ya que es causa frecuente de discapacidad, dependencia y aumento de la morbimortalidad. En la presente revisión bibliográfica del tema, analizamos los diferentes factores etiológicos y las estrategias de prevención y tratamiento de la sarcopenia, entre las que el ejercicio, y en particular el entrenamiento de fuerza, junto con una alimentación adecuada, desempeñan un papel primordial.

© 2011 Revista Andaluza de Medicina del Deporte.

Correspondence:
J. de D. Beas-Jiménez.
Centro Andaluz de Medicina del Deporte.
Consejería de Turismo, Comercio y Deporte de la
Junta de Andalucía.
Glorieta Beatriz Manchón, s/n.
41092 Sevilla. Spain.
E-mail: juand.beas@juntadeandalucia.es

Introduction

After reaching adulthood, humans and most mammals suffer a progressive decline of strength and muscle mass as time goes by. This is accompanied by a functional capacity loss and a raise of fat in muscle. Importantly, all these factors affect quality of life of the elderly causing frailty, dependency and the increase of morbi-mortality[1-5]. This progressive deterioration of muscle capacity is known as sarcopenia (From the Greek: *sarco*: muscle and *penia*: wasting, loss). In a classical way, an individual was considered as suffering sarcopenia when muscle parameters values were lower than two standard deviations from the values of a referenced young population. However, the current tendency includes in the definition of sarcopenia some other parameters related to strength, functional capacity of the subject and corporal fat amount[6,7]. This tendency distinguishes between an aging-dependent process (primary sarcopenia) and a pathological process (secondary sarcopenia)[8-16]. New concepts such as dinapenia or the age-associated loss of strength[17] or new techniques such as proteomics[18] or genomics[19] must be considered in future studies of this pathology.

Etiology and particular characteristics of sarcopenia in the elderly

Several authors indicate that muscle mass reaches the maximum amount around the 30s and after that, it declines at a rate of 3-8% per decade. Decline rhythm accelerates from the 50s reaching 12-15% per decade[9,11,20]. Women show a higher decrease of muscle mass, especially after menopause. Regarding muscle quality, the capacity to produce strength per unit of muscle, different longitudinal studies have reported an important decrease during aging[9,21-25]. European population data about sarcopenia prevalence in people older than 65 years indicate a ratio moving from 9.5 to the 15.7%. These values rise as the population get older[13]. When compared with woman showing normal bone mineral density (0.8%), sarcopenia is more frequent in women suffering osteopeny (25%) and osteoporosis (50%)[2]. This relationship is probably due to related etiological mechanisms[26]. Furthermore, we can speculate that physical activity, able to maintain muscle mass, will help to maintain bone mass. This effect will be especially good in women since they show higher osteoporosis prevalence[27].

The reduction of muscle mass in aged people does not affect in the same way to arms and legs. Muscle wasting is higher in lower limbs with independency of the sex of the person. However, when functional parameters, such as muscle quality, are taken into consideration, we can find sex-dependent differences. Men suffer a higher loss in upper limbs than women whereas no differences in the deterioration of muscle mass rate in lower limbs have been found. These differences could be due to the fact that women are more able to maintain a higher activity in arms due to domestic duties[11,28]. Reduction of muscle mass in lower limbs is, however, more important since it produces a severe functional decline in people's capacity[29].

Aging-related sarcopenia seems to depend on the chronic inflammation process affecting most of the elderly[30], aggravated by fat infiltration in the muscle[11,31] and sarcopenic obesity. Sarcopenic obesity is characterized by the pathological increase of body fat accompanied by a decrease in muscle and bone mass. In these patients, excessive amount of calories in the diet produces a higher loss of muscle mass[32]. Obesity seems to contribute, even more than sarcopenia, to the lower functional capacity of these subjects[6]. Further, co-morbid diseases common to older individuals such as cancer, kidney disease, diabetes and peripheral artery disease can also accelerate the progression of sarcopenia in elderly people[33].

Two mechanisms are involved in the decrease of the muscle mass in humans: reduction of the number of muscle fibres and reduction of the cross-sectional area of existing fibres. Aging does not affect in the same way to all the types of fibres. Type II fibres are the most affected. In consequence, important functional incapacity appears due to the decrease of production of rapid strength or to carry out power in muscle[31,34]. This is due to the lower resistance of this kind of fibres to the denervation[11,35], deficiencies in gene expression of myosin type II[35,36] and a lower resistance of these fibres to oxidative stress[37]. All these mechanisms could be related to testosterone deficit found in old people[34].

Reduction of muscle fibre mass is also produced by intrinsic factors in myocytes. In aged people muscle mitochondria dysfunction accumulates. This deleterious effect is caused by accumulation of mtDNA damage that negatively affects the metabolic rate, protein synthesis and ATP production. Al these effects end in the death of the muscle fiber[11,38]. Moreover, regeneration and repair mechanisms of muscle fibre are also compromised in elderly people due to a lower activity of satellite cells[31], chronic inflammation[39], oxidative stress[35,40], abnormal response of the microRNA[41] and an inadequate regulation of the repair processes in damaged muscle fibres[39].

Aged muscle is characterized by a delay in the peak of muscle contraction, an increase in the time of muscle relaxation, diminution in strength and reduction of the oxidative metabolic capacity[35,42]. These alterations are due to the accumulation of oxidative stress damaged proteins and DNA, especially mtDNA[35,43], mitochondrial dysfunction, alteration of the transport of calcium[35,40] and malfunction of contractile proteins[37]. Disappearance of muscle fibres forces to surviving fibres to compensate, or partially correct the compelled deficit to maintain the optimal capacity to generate strength[44].

All these reasons permit us to affirm the multifactorial etiology of sarcopenia[9-11,16,20,27,30-31,35,37-40,42,45-63]. The different concerned mechanisms involved in muscle loss are indicated in table 1 and figure 1.

Prevention and treatment of sarcopenia

Physical exercise, nutrition and pharmacological approaches have been proposed as mechanisms for and treatment of sarcopenia[10-11,16,35,64-79]. However, to date, no pharmacological procedures have demonstrated any efficiency in the prevention of sarcopenia in humans[62]. This pharmacological inefficacy must be due to the complexity of sarcopenia. For this reason, clinical trials of drug testing for treatment of sarcopenia must include significant improvement of physical performance, falls, fractures and functionality and quality of life[80].

Preventive measures must be maintained during the whole life of the person. These measures consist in the practice of regular resistant and aerobic exercise and an equilibrated diet. These mechanisms require the increment of the uptake of high-quality proteins, showing fast absorption and high contents of leucine[11,12,35,49,58,81], adequate uptake of antioxidants, caloric restriction and reduction of the deficit of vitamin D or inappropriate loss of weight[10-11,54-56,62,82-85]. Nutritional measures are of special interest because elderly people showing recurrent pathologies[86] or in the case of sarcopenia-suffering obese old people[85], reduce physical

Table 1
Main etiological mechanisms involved in sarcopenia

Mechanism	
Nervous	Reduction of the number of alfa motoneurons
	Reduction of the number of motor units
	Decrease of the nervous transmission speed
	Demyelination
	Reinnervation after lost of motoneurons
	Reduction of the coupling excitation-contraction
	Deficient coordination of agonists-antagonists
	Reduction of the neuromuscular activation capacity
Muscle	Decrease of fibre number
	Decrease of muscle quality
	Reduction of proliferation of satellite cells
	Impairment of repair and regeneration processes
	IGF-I resistance
	Fat infiltration
	Mitochondrial dysfunction
	Deterioration of muscle proteins
	Alterations in muscle macrophage function
	Reduction of the actin-myosin bridges
	Reduction in the number of sarcomers (serial and in parallel)
Hormonal and endocrine	Decreased levels of growth hormone, IGF-1, testosterone, dehidroepiandrosterone (DHEA), insulin, estrogens
	Resistance to insulin action
	Higher levels of parathyroid hormone
	Higher levels of cortisol and leptin
	Obesity (higher levels of IL-6, lower levels of testosterone and growth hormone, insulin-resistance, intracellular deposits in muscle fibres, subclinical inflammation)
	Increase of abdominal fat
Humoral	Higher levels of proinflammatory interleukins (IL-6, IL-1, TNF-α, TGF-β)
	Lower levels of anti-inflammatory interleukins (IL-1Ra [IL-1 receptor antagonist], IL-4, IL-10, IL-13)
	Rise in soluble TNF receptor, (sTNFR1)
	Rise in C-reactive protein (CRP)
	Increase in inflammation mediators (NF-βB, SOCS3, PGC-1, heat shock proteins, reactive oxygen and nitrogen species)
	Myostatin
	Angiotensin II
	Oxidative stress
	Caspases
	SRF (serum response factor)
	Higher levels of neutrophils
Apoptosis	Disorders in mitochondrial DNA
	Mitochondrial dysfunction
	Apoptosis disregulation
	Electron transport chain disruption
Life style/Disease	Sedentarism
	Smoking
	Immobilization
	Resting in bed
	Chronic diseases
Nutrition	Malnutrition
	Low intake of protein and essential aminoacids
	Intake of low-quality proteins
	Loss of appetite
	Deficiency in vitamin D
Genetics	Programming
	Developmental plasticity
	Phenotypical expression
	Muscle proteins expression
	Gene expression for proteolytic proteins (FOXO3A and MuRF-1)

activity. In fact, in the obese sarcopenic elder, physical exercise, together with a moderated caloric restriction, seems to be the optimal method to reduce fat mass and avoid the muscle mass wasting[85].

The metabolic effect produced by resistance exercise in old people must be accompanied by an adequate protein intake[58]. Since ancients show a decrease in the protein metabolism[87], it is recommended that protein intake must be at least 1.0 to 1.3 g/kg body weight per day. This intake must be homogeneously distributed among all the meals during the day. Further, these proteins must show a high biological quality as higher content of branched-chain aminoacids (BCAA) such as leucine. Other nutritional measures such as antioxidant dietary supplementation, omega-3 acids or compensation of the vitamin D deficit have demonstrate to be efficient in the treatment of sarcopenia[16,62,83,88,89]. These nutritional measures are very important when muscle catabolism increases because inactivity periods[86].

Regarding pharmacological procedures against sarcopenia, several pharmacological compounds have been used. However, their secondary effects and their moderated or null effect advise against their use in the treatment of muscle wasting. Some of these compounds such as angiotensin I to II-conversion inhibitors (ACE Inhibitors), simvastatin, androgenic receptor selective agonists, ibuprofen and paracetamol have demonstrated some efficacy in the treatment of sarcopenia. However, their definitive role in this pathology needs to be clarified[11,12,20,35,77,78,90,91].

Role of physical exercise in prevention and treatment of sarcopenia

Resistance exercise

Resistance exercise o muscle potentiation has demonstrated a great efficacy in the treatment and prevention of sarcopenia. In fact, increases in muscle mass, strength and quality and also a better neuromuscular adaptation have been reported after the practice of exercise programs including different exercise protocols[11,12,16,35,58,67,92-97]. After analyzing the different recommendations of several associations such as the American College of Sport Medicine and the American Heart Association, and the results of the main studies performed about exercise, aging and sarcopenia, we suggest that the recommended exercise must contain resistance training including several exercises circuits with the 70-90% of the one repetition maximum (RM), with an exercise predominantly eccentric and performed, at least, every two non-consecutive days[11,35,58,93,98,99]. Since the abandon of the resistance training ends in a fast waste of muscle mass, we advise that a maintenance exercise must be performed including, at least, a week session with the above indicated exercises and intensities[100-102]. However, the clinical status of elderly people must be taken into consideration and obliges to individualize training programs[35].

Furthermore, several other added beneficial effects of resistance exercise to the health of elderly people must be taken into consideration. In fact, the practice of physical exercise also exerts a positive effect in the preservation of cognitive function[5].

Aerobic exercise

Aerobic exercise delays the strength loss and phenotypic changes produced during aging in muscle fibers[35,84], even at moderated intensities[101]. However, the effects of aerobic exercise are modest and its definitive effect on sarcopenia is not completely clarified[62]. Then, it seems clear that the combination of both, resistance and aerobic exercises is more healthy for elderly people since it produces multiple benefits preventing and treating prevalent diseases at old ages[5,31,59,62] or in particular situations such as sarcopenic obesity[32,52,85].

Fig. 1. Scheme of the different etiological sarcopenia mechanisms and their consequences.

Mechanisms of action of exercise on sarcopenia

There are multiple mechanisms by which resistance exercise prevents and ameliorates sarcopenia. We considered that it is worth to detail these mechanisms. Although these mechanisms are widely overlapped, we will analyze the effects of resistance exercise at muscle and neuromotor levels (fig. 1).

At the muscle level

At the muscle level, resistance exercise neutralizes several of the mechanisms involved in the development of sarcopenia. This kind of exercise induces positive changes in the inflammation status, apoptosis of muscle fibre, regeneration of these fibres and the function and anatomy of muscle. Regarding the function of muscle, resistance exercise increase muscle quality through the increase in the number of sarcomera in parallel but also serial number[103], by increase of the rigidity and the longitudinal elastic module (Young's module) of tendons[27,104].

Subclinical inflammation is one important etiological factor in sarcopenia. Resistance exercise reduces the chronic status of inflammation in elderly people by decreasing the level of pro-inflammatory mediators produced by monocytes/macrophages, increasing the production of anti-inflammatory cytokines or reducing the inflammatory response to acute exercise. Furthermore, resistance exercise also reduces the expression of genes encoding proteolytic proteins and increases the expression of antioxidant enzymes[30,39,50]. Since the increase in fat mass and the reduction of the levels of sexual hormones is related to the increase of pro-inflammatory cytokines[11], the reduction of the amount of fat mass and infiltrated muscle fat by the practice of resistance exercise is other of the mechanisms by which exercise would reduce the chronic inflammatory status in elderly population showing sarcopenic obesity.

Apoptosis is other of the mechanisms involved in the development of muscle fibre loss during sarcopenia in the elderly. A session of acute exercise induces the apoptosis machinery in some of the muscle fibres. Moreover, this apoptosis is also a stimulus for the reparation machinery in muscle. For this reason, acute exercise also stimulates the process of muscle regeneration. When it is practiced regularly, exercise induces important and beneficial adaptations in apoptotic pathways such as a lower activity in caspases, lower amounts of proapoptotic proteins, increase of the expression of anti-apoptotic genes and increase in the levels of anti-apoptotic markers[26,54]. Caloric restriction plays an important adjuvant role to the beneficial effects of exercise since it also contributes to the reduction of apoptosis in muscle fibers[10,54].

Mitochondrial dysfunction found in aged people is due to the accumulation of oxidative damage in lipids, proteins and mitochondrial DNA. This dysfunction jeopardizes the production of energy in muscle fibres and reduces the physical capacity in old people[35,42,43]. The practice of both, resistance and aerobic exercise reduces these adverse effects of aging[11,38,105-107].

Reparation and regeneration mechanisms degenerate as years accumulate[27,31,39,41]. One of the activation pathways in the regeneration of damaged muscle fibres depends on Insulin-like growth factor (IGF). The isoform I (IGF-I) promotes proliferation and differentiation of myoblasts and induces protein synthesis in muscle whereas the isoform II (IGF-II)

promotes the differentiation of satellite cells. Then, IGF benefits muscle recovering by stimulating anabolism in muscle fibres and activating proliferation and differentiation of satellite cells[27,31]. In old people, muscle maintains the capacity to produce IGF-I, but shows resistance to its action. On the other hand, exercise increases the capacity to produce IGF-I, the synthesis of its receptors and the activity of the IGF-I-dependent pathways[31,98,108-111]. Eccentric exercises, that at the beginning induce a higher muscle damage in comparison with concentric contraction, increase levels of IGF-I mRNA in muscle[98]. Then, eccentric exercises will be especially indicated for the treatment of elderly people suffering sarcopenia. Other authors[5] have related the increase in the sensibility to IGF-I and the decrease in the levels of homocystein produced by the practice of resistance exercise, with the prevention of cognitive decay induced by this type of exercise.

Since sarcopenia in the elder affects predominantly to type II fibres and training of muscle strength, through vibratory platforms, increase the number of these fibres, this kind of training would be recommended for the treatment and prevention of sarcopenia, specially because its security, efficacy and simplicity[112-115]. The physiological arguments of this methodology for training are based on the fact that the capacity of blunting of the vibratory stimulus depends on the viscoelastic properties of the individual. This means that this capacity depends on the stiffness produced by the structures of the organism and, in this case, this rigidity depends on the activation level of the receptors of the muscle use, the skin and joints or on the proportion of muscle type II fibres in the person. These factors are compromised in different degree in elderly people[116,117]. Other factors contributing to the increase of muscle stiffness are the incoordination agonist-antagonist[118-121] and the increase in the rigidity of the tendons[104]. These data would reinforce the use of vibrating platforms with subjects suffering sarcopenia.

Neuromotor level

After the performance of strength training programs the increase found in muscle strength is higher than the increase in muscle mass. This fact highlights the importance of the neuromuscular adaptations induced by this type of exercise. These adaptations consist in better muscle innervations and improved muscle activation patterns[11,17] by increases of muscle nervous stimuli from central nervous system, improvement of the synchronization[122], changes in the commitment[118] and increase in the maximum unloading rate in motor units[35], decrease of the co-activation of antagonist muscles[119-121], and increase in the expression of genes participating in the function and plasticity of synapse[19].

Dynapenia, muscle weakness in the elderly, depends on alterations in muscle quantity, contractile quality and also neuronal activation. In this case, maintenance of the neuromuscular function through the practice of physical exercise seems to be essential for maintaining muscle strength and physical independence in old people[123].

Molecular level

Since muscle wasting indicates a deregulation of the mechanisms involved in the maintenance of muscle fibres, a better understanding of the metabolic processes involved in the regulation of muscle mass is critical. This knowledge will permit us to design and develop more effective therapies to prevent this process[124]. Among the factors implicated in sarcopenia, the deregulation of muscle protein synthesis is one of the most frequently reported. Thus, the possible mechanisms to treat or prevent sarcopenia must include the regulation of the molecular factors that contribute to the balance between protein synthesis and breakdown[125]. One of the main signalling pathways controlling protein synthesis in skeletal muscle is depending on the kinase Akt/PKB. One of the main targets of Akt/PKB is the mammalian target of rapamycin (mTOR) kinase that has been recently shown as a key sensor of nutritional status and lifespan. In fact, animal studies have demonstrated that Akt/mTOR-dependent pathway is downregulated in muscle during aging[126]. Furthermore, it has been demonstrated that this anabolic pathway show a delayed response to both, strength exercise and essential aminoacid treatment in aged in comparison with young people[127]. These effects can probably due to the oxidative modification of Akt by s-nitrosylation that contributes to a lower activity and then, regulation of downstream targets even with higher levels of Akt[128]. This delayed response is probably due to the insulin resistance that increases during aging since some experiments have demonstrated that supraphysiological doses of insulin can induce protein anabolism in muscle in aged people[129]. Since aerobic exercise have demonstrated its capacity to overcome insulin-resistance in muscle[130], the combination of both, aerobic and strength exercise must increase the response of muscle and increase the activity of the Akt/mTOR dependent protein anabolism.

On the other hand, mitochondrial activity is other of the main factors involved in the maintenance of the activity of muscle fibres. Caloric restriction is one of the main therapies able to increase life-span and increase muscle capacity of the organisms tested during aging. This nutritional intervention prevents mitochondrial damage by improving the metabolic balance and avoiding oxidative stress[131]. Then, a balanced aerobic metabolism will prevent mitochondrial damage and probably will delay sarcopenia progression. Thus, prevention of mitochondrial damage could be one of the key mechanisms to delay or avoid sarcopenia. Recently, studies performed in mouse models for mitochondrial mutations have demonstrated that exercise prevents mitochondrial dysfunction and apoptosis in sarcopenia by increasing mitochondrial remodeling[51,132,133], indicating the importance of functional mitochondria in muscle maintenance.

Biogenesis of mitochondria depends on multiple factors that converge in the activation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1-α)[134]. This factor is the centre of a system of gene induction that regulates the renovation of mitochondrial components and maintains mitochondria function. PGC-1-α itself is regulated by several factors including AMP-activated protein kinase (AMPK). AMPK is a key sensor of the metabolism and nutritional status of the cell[135]. Activity of AMPK is also negatively affected by aging contributing to the decrease of mitochondrial biogenesis and, then, sarcopenia. Furthermore, prevention of mitochondrial damage by increasing antioxidant activities has been recently shown to prevent age-associated mitochondrial function and improve insulin resistance[136]. This fact will permit to maintain a better oxidative metabolism at the same time that improves protein anabolism by increasing insulin sensibility. However, in old organisms, mitochondriogenesis induced by exercise seems to be limited[137], although, some reports in humans indicate induction of this pathway at old ages[138,139], probably by inducing the activity of sirtuins, key factors in longevity and mitochondrial metabolism[134,140,141].

Finally, mitochondrial biogenesis must be balanced with the elimination of old and damaged mitochondria by mitophagy to maintain a balanced metabolism and avoid oxidative damage produced by higher release of reactive oxygen species (ROS). In this process, fork-head box

Fig. 2. Molecular mechanisms involved in sarcopenia. Basic representation of the molecular mechanisms involved in sarcopenia. Activity of AMPK, Akt/PKB and IGF-R-dependent mechanisms are reduced during aging. Practice of exercise, a low calorie diet and the intake of high quality aminoacids are able to induce the activity of the different components and stimulate protein synthesis and mitochondrial biogenesis. At the same time, Akt and AMPK also control mito-autophagy and proteasome activity. The knowledge of how these pathways are affected during aging and its effect on sarcopenia and the mechanism of action of exercise and diet on the activity of the main components of these pathways will permit us to develop therapeutical and pharmacological strategies to reduce sarcopenia during late ages.

(FOXO)-dependent mechanism must be taken into consideration. In muscle, FOXO3 regulates the expression of both, proteasome-dependent mechanisms of protein catabolism and auto-mitophagy. Both mechanisms are involved in muscle wasting[142-144]. On the other hand, activation of PGC-1-α expression in muscle inhibits FOXO-dependent protein degradation and prevents atrophy[145,146]. At the same time, exercise is able to increase both, protein synthesis machinery at the same time that induces proteasome-dependent activity indicating a mechanism of protein remodelling in muscle fibre[147].

All these mechanisms are differently affected by the type of exercise performed, by quality of nutrients and amount of calories (fig. 2). Further, other hormonal effectors must be taken into consideration to understand the complex system involved in muscle physiology. It seems clear that intracellular signalling pathways are negatively affected by aging and that those mechanisms able to increase their activity during aging are important to avoid or, at least, delay sarcopenia.

Other mechanisms

Resistance mechanism improves the hormonal profile of old people specially affecting the levels of testosterone[20,90,148], growth hormone[11-13,26], estrogens[78,92,149], IGF-I[11,20,26,31,79,98,108-111] and insulin and improve the response to insulin[20] preventing and improving by these means muscle capacity and, then, at least, reducing the progression of sarcopenia.

Conclusions

Resistance training, added to an adequate nutrition and aerobic exercise, is one of the main tools to prevent and treat sarcopenia in the elderly.

References

1. Cosquéric G, Sebag A, Ducolombier C, Thomas C, Pierre F, Weill-Engerer S. Sarcopenia is predictive of nosocomial infection in careo f the elderly. Brit J Nutrit. 2006;96:895-901.
2. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int. 2006;17:61-7.
3. Abate M, Di Iorio A, Di Renzo D, Paganelli R, Saggini R, Abate G. Frailty in elderly: the physical dimension. Eura Medicophys. 2007;43:407-15.
4. Auyeung TW, Kwok T, Lee J, Leung PC. Functional decline in cognitive impairment – The relationship between physicl and cognitive function. Neuroepidemiology. 2008;31:167-73.
5. Liu-Ambrose T, Donalson MG. Exercise and cognition in older adults: is there a role for resistance training programmes? Br J Sports Med. 2009;43:25-7.
6. Bouchard DR, Dionne IJ, Brochu M. Sarcopenic/Obesity and physical capacity in older men and women: data from the nutrition as a determinant of successful aging (NuAge) – The Quebec Longitudinal Study. Obesity. 2009;17:2082-8.
7. Jensen GL, Hsiao PY. Obesity in older adults: relationship to functional limitation. Curr Opin Clin Nutr Metab Care. 2010;13:46-51.
8. Argilés JM, Busquets S, López-Soriano FJ, Figueras M. Fisiología de la sarcopenia. Similitudes y diferencias con la caquexia neoplásica. Nutr Hosp. 2006;21(Supl 3):38-45.
9. Serra JA. Consecuencias clínicas de la sarcopenia. Nutr Hosp. 2006; 21(Supl 3):46-50.

10. Naylor AJ, Leeuwenburgh C. Sarcopenia: the role of apoptosis and modulation by caloric restriction. Exerc Sport Sci Rev. 2008;36:19-24.

11. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12:433-50.

12. Abellan Van Kan G, Andre E, Bischoff-Ferrari HA, Boirie Y, Onder G, et al. Carla task force on sarcopenia: propositions for clinical trials. J Nutr Health Aging. 2009a;13:700-7.

13. Abellan Van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009b;13:708-12.

14. Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging. 2009;13:724-8.

15. Visser M. Towards a definition of sarcopenia – Results from epidemiologic studies. J Nutr Health Aging. 2009;13:713-6.

16. Thomas DR. Sarcopenia. Clin Geriatr Med. 2010;26:331-46.

17. Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci. 2008;63:386-91.

18. Doran P, Donoghue P, O'Connell K, Gannon J, Ohlendieck K. Proteonics of skeletal muscle aging. Proteomics. 2009;9:989-1003.

19. Hollmann W, Strüder HK, Tagarakis CV, King G. Physical activity and the dlderly. Eur J Cardiovasc Prev Rehabil. 2007;14:730-9.

20. Burgos R. Enfoque terapéutico global de la sarcopenia. Nutr Hosp. 2006;21(Supl 3):51-60.

21. Young A, Stokes M, Crowe M. The size and strength of the quadriceps muscles of old and young men. Clin Physiol. 1985;5:145-54.

22. Klitgaard H, Mantoni M, Schiaffino S. Function, porphology and protein expression of ageing skeletal muscle: a cross-sectional study of ederly men with different training backgrounds. Acta Physiol Scand. 1990;140:41-54.

23. Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserverd by hormone replacement therapy. Clin Sci. 1993;84:95-8.

24. Macaluso A, Nimmo MA, Foster JE, Cockburn M, McMillan NC, De Vito G. Contractile muscle volume and agonist-antagonist coactivation account for differences in torque between young and older women. Muscle Nerve. 2002;25:858-63.

25. Morse CI, Thom JM, Davis MG, Fox KR, Birch KM, Narici MV. Reduced plantarflexor specific torque in the ederly is associated with a lower activation capacity. Eur J Appl Physiol. 2004;92:219-26.

26. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol. 2010;205:201-10.

27. Narici MV, Maganaris CN. Adaptability of elderly human muscles and tendons to increased loading. J Anat. 2006;208:433-43.

28. Jansen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol. 2000;89:81-8.

29. Reid KF, Naumova EN, Caraballo RJ, Phillips EM, Fielding RA. Lower extremity muscle mass predicts functional performance in mobility-limited elders. J Nutr Health Aging. 2008;12:493-8.

30. Nicklas BJ, Brinkley TE. Exercise training as a treatment for chronic inflammation in the elderly. Exerc Sport Sci Rev. 2009;37:165-70.

31. Adamo ML, Farrar RP. Resistance training, and IGF involvement in the maintenance of muscle mass Turing the aging process. Ageing Res Rev. 2006;5:310-31.

32. Miller SL, Wolfe RR. The danger of weight loss in the elderly. JNHA. 2008;12:487-91.

33. Buford TW, Anton SD, Judge AR, Marzetti E, Wohlgemuth SE, Carter CS, et al. Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy. Ageing research reviews. 2010;9:369-83.

34. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, Van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibres in the elderly. Am J Physiol Endocrinol Metab. 2007;292:E151-7.

35. Jones T, Stephenson KW, King JG, Knight KR, Marshall TL, Scott WB. Sarcopenia – mechanisms and treatments. J Geriat Phys Ther. 2009;32:39-45.

36. Balagopal P, Schimke JC, Ades P, Adey D, Nair KS. Age effect on transcript levels and synthesis rate muscle MHC and response to resistance exercise. Am J Physiol Endocrinol Metab. 2001;280:E203-8.

37. Thompson LV. Age-related muscle dysfunction. Exp Gerontol. 2009;44:106-11.

38. Waters DL, Brooks WM, Qualls CR, Baumgartner BN. Skeletal muscle mitocondrial function and lean body mass in healthy exercising elderly. Mech Ageing Dev. 2003;124:301-9.

39. Peake J, Della Gatta P, Cameron-Smith D. Aging and its effects on inflammation in skeletal muscle at rest and following exercise-induced muscle injury. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1485-95.

40. Dargelos E, Poussard S, Brulé C, Daury L, Cottin P. Calcium-dependent proteolytic system and muscle dysfunctions: A possible role of calpains in sarcopenia. Biochimie. 2008;90:359-68.

41. Drummond M, McCarthy JJ, Fry CS, Esser K, Rasmussen BB. Aging differentially affects human skeletal muscle microRNA expression at rest and after an anabolic stimulus of resistance exercise and essential amino acids. Am J Physiol Endocrinol Met. 2008;295:1333-40.

42. Waters DL, Mullins PG, Qualls CR, Raj DR, Gasparovic C, Baumgartner RN. Mitocondrial function in physically active elders with sarcopenia. Mech Ageing Dev. 2009;130:315-9.

43. Bokov A, Chaudhuri A, Richardson A. The role of oxidative damage and stress in aging. Mech Ageing Dev. 2004;125:811-26.

44. Frontera WR, Reid KF, Phillips EM, Krivickas LS, Hughes VA, Roubenoff R, et al. Muscle fibre sice and function in elderly humans: a longitudinal study. J Appl Physiol. 2008;105:637-42.

45. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I locks the aging-related loss of skeletal muscle function. Porc Natl Acad Sci USA. 1998;95:15603-7.

46. Schach E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue. 1999;65:317-27.

47. Siriett V, Platt L, Senna M, Ling N, Kambadur R, Sharma M. Prolonged absence of myostatin reduces sarcopenia. J Cel Physiol. 2006;209:866-73.

48. Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? A conceptual review. Cancer. 2007;110:2604-13.

49. Chaput JP, Lord C, Cloutier M, Aubertin-Leheudre M, Goulet ED, Rousseau S, et al. Relationship between antioxidant intakes and class I sarcopenia in elderly men and women. J Nutr Health Aging. 2007;11:363-9.

50. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol. 2007;62A:1407-12.

51. Hiona A, Leeuwenburgh C. The role of mitochondrial DNA mutations in aging and sarcopenia: implications for the mitochondrial vicious cycle theory of aging. Exp Gerontol. 2008;43:24-33.

52. Jensen GL. Inflammation: roles in aging and sarcopenia. J Parent Enter Nutr. 2008;32:656-9.

53. Lahouete C, Sotiropoulos A, Favier M, Guillet-Deniau I, Charvet C, Ferry A, et al. Premature aging in skeletal muscle lacking serum response factor. PloS One. 2008;3:e3910.

54. Marzetti E, Lawler JM, Hiona A, Manini T, Seo AY, Leeuwenburgh C. Modulation of age-induced apoptotic signaling and cellular remodeling by exercise and calorie restriction in skeletal muscle. Free Rad Biol Med. 2008;44:160-8.

55. Sayer AA, Syddall H, Martin H, Pael H, Baylis D, Cooper C. The developmentl origins of sarcopenia. J Nutr Health Aging. 2008a;12:427-32.

56. Sayer AA, Dennison E, Syddall HE, Jameson K, Marin HJ, Cooper C. The developmental origins of sarcopenia: using peripheral quantitative computed tomography to assess muscle size in older people. J Gerontol A Biol Sci Med Sci. 2008b;63:835-40.

57. Waters DL, Qualls CS, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol Med Sci. 2008;63A:536-41.

58. Boirie Y. Phisiopathological mechanism of sarcopenia. J Nutr Health Aging. 2009;13:717-23.

59. Booth FW, Zwetsloot KA. Basic concepts about genes, inactivity and aging. Scand J Med Sci Sports. 2010;20:1-4.

60. Paul E, Cronan R, Weston PJ, Boekelheide K, Sedivy JM, Lee SY, et al. Disruption of Supv3L1 damages the skin, and causes sarcopenia, loss of fat, and death. Mamm Genome. 2009;20:92-108.

61. Shah VO, Scariano J, Waters D, Qualls C, Morgan M, Pickett G, et al. Mitochondrial DNA deletion and sarcopenia. Genet Med. 2009;11:147-52.

62. Visvanathan R, Chapman I. Preventig sarcopaenia in older people. Maturitas. 2010;66:383-8.

63. Clark DJ, Patten C, Reid KF, Carabello RJ, Phillips EM, Fielding RA. Muscle performance and physical function are associated with voluntary rate of neuromuscular activation in older adults. J Gerontol A Biol Sci Med Sci. 2011;66:115-21.

64. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG, Evans WJ. Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol. 1988;64:1038-44.

65. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. Hingh-intesity strenght training in nonagenarians. Effects on skeletal muscle. JAMA. 1990;263:3029-34.

66. Charete SL, McEvoy L, Pika G, Snow-Harter C, Guido D, Wiswell RA, et al. Muscle hypertrophy response to resistance training in older women. J Appl Physiol. 1991;70:1912-6.

67. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, et al. Exercise training and nutricional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769-75.

68. Lexell J, Downhm DY, Larsson Y, Bruhn E, Morsing B. Heavy-resistance training in older Scandinavian men and women: short- and long-term effects on arm and leg muscles. Scan J Med Sci Sports. 1995;5:329-41.

69. Carmeli E, Reznick AZ, Coleman R, Carmeli V. Muscle strength and mas of lower extremities in relation to functional abilities in ederly adults. Gerontology. 2000;46:249-57.

70. Connelly DM, Vandervoort AA. Effects of isokinetics strength training on concentric and eccentric torque development in the ankle dorsiflexors of olders adults. J Gerontol A Biol Sci Med Sci. 2000;55:B465-72.

71. Roth SM, Ivey FM, Martel GF, Lemmer JT, Hurlbut DE, Siegel EL, et al. Muscle size responses to strength training in young and older men and women. J Am Geriat Soc. 2001;49:1428-33.

72. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA, et al. Resistance exercise and physical performance in adults aged 60 to 83. J Am Geriatr Soc. 2002;50:1100-7.

73. Bamman MN, Hill VJ, Adams GR, Haddad F, Wetzstein CJ, Gower BA, et al. Genders differences in resistance-training-induced myofiber hypertrophy among older adults. J Gerontol A Biol Sci Med. 2003;58:108-16.

74. Brose A, Parise G, Tarnopolsky MA. Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J Gerontol A Biol Sci Med. 2003;58:11-9.

75. Ferri A, Scaglioni G, Pousson M, Copodaglio P, Van Hoecke J, Narici MV. Strength and power changes of the human plantar flexor and knee extensors in response to resistance training in older age. Acta Physiol Scand. 2003;177:69-78.

76. Frontera WR, Hughes VA, Krivickas LS, Kim SK, Foldvari M, Rubenoff R. Strength training in older women: early and late changes in whole muscle and single cells. Muscle Nerve. 2003;28:601-8.

77. Zamora E, Galan A, Simó R. Papel de la miostatina en la afectación muscular asociada a las enfermedades crónicas. Med Clin (Barc). 2008;131:585-90.

78. Onder G, Della Vedova C, Landi F. Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia. J Nutr Health Aging. 2009;13:746-56.

79. Kandala PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011;132:154-62.

80. Brass EP, Sietsema KE. Considerations in the development of drugs to treat sarcopenia. J Am Geriat Soc. 2011;59:530-5.

81. Morais JA, Chevalier S, Gougeon R. Protein turnover and requirements in the healthy and frail elderly. J Nutr Health Aging. 2006;10:272-83.

82. Houston DK, Nicklas BJ, Ding J, Harris TB, Tylavsky FA, Newman AB, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr. 2008;87:150-5.

83. Rodríguez-Bíes E, Santa-Cruz Calvo S, Navas P, López-Lluch G. Resveratrol: an ergogenic compound. Rev Andal Med Deporte. 2009;2:12-8.

84. Park H, Park S, Shephard RJ, Aoyagi Y, Yeralong physical activity and sarcopenia in older adults: the Nakanojo Study. Eur J Appl Physiol. 2010;109:953-61.

85. Han TS, Tajar A, Lean ME. Obesity and weight management in the elderly. Br Med Bull. 2011;97:169-96.

86. English KL, Paddon-Jones D. Protecting muscle mass and function in o lder adults during bed rest. Curr Opin Clin Nutr Metab Care. 2010;13:34-9.

87. Pennings B, Koopman R, Beelen M, Senden JM, Saris WH, Van Loon LJ. Exercising before protein intake allows for greater use of dietary protein-derived amino acids for de novo muscle protein synthesis in both young and elderly men. Am J Clin Nutr. 2011;93:322-31.

88. Kim JS, Wilson JM, Lee SR. Dietary implications on mechanisms of sarcopenia: roles protein, amino acids and antioxidants. J Nutr Biochem. 2010;21:1-13.

89. Smith GI, Atherton P, Reeds DN, Mohammed BS, Rankin D, Rennie MJ, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in olders adults: a randomiced controlled trial. Am J Clin Nutr. 2011;93:402-12.

90. Kovacheva EL, Sinha Hikim AP, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin,c-Jun NH$_2$-terminal kinase, Notch, and Akt signaling pathways. Endocrinology. 2010;151:628-38.

91. Trappe TA, Carroll CC, Dickinson JM, Lemoine JK, Haus JM, Sullivan BE, et al. Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol. 2011;300:R655-62.

92. Messier V, Rabasa-Lhoret R, Barbat-Artigas S, Elisha B, Karelis AD, Aubertin-Leheudre M. Menopause and sarcopenia: a potential role for sex hormones. Maturitas. 2011;68:331-6.

93. Borst SE. Intervention for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33:548-55.

94. Hunter GR, McCarthy JP, Bamman M. Effects of resistance training on older adults. Sports Med. 2004;34:329-48.

95. Macaluso A, De Vito G. Muscle strength, power and adaptations to resistance training in older people. Eur J Appl Physiol. 2004;91:450-72.

96. Marini M, Sarchielli E, Brogi L, Lazzeri R, Salerno R, Sgambati E, et al. Role of adapted physical activity to prevent the adverse effects of the sarcopenia. A pilot study. It J Anat Embryol. 2008;113:217-26.

97. Liu C, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database of Systematic Reviews. 2009; Issue 3. Art. No.: CD002759.

98. Bamman MM, Shipp JR, Jiang J, Gower BA, Hunter GR, Goodman A, et al. Mechanical load increases muscle IGF-I and androgen receptor mRNA concentration in humans. Am J Physiol Endocrinol Metab. 2001;280:E383-90.

99. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1094-105.

100. Häkkinen K, Kallinen M, Izquierdo M, Jokelainen K, Lassila H, Mälkiä E, et al. Changes in agonist-antagonist EMG, muscle CSA, and force during strenght training in middle-aged and older people. J Appl Physiol. 1998;84:1341-9.

101. Taafe DR. Once-weekly resistance exercise improves muscle strenght and neuromuscular performance in older adults. J Am Geriatr Soc. 1999; 47:1208-14.

102. Bickel CS, Cross JM, Bamman MM. Exercise Dosing to Retain Resistance Training Adaptations in Young and Older Adults. Med Sci Sports Exerc. 2010;43:1177-87.

103. Reeves ND, Narici MV, Maganaris CN. In vivo human muscle structure and function: adaptations to resistance training in old age. Exp Physiol. 2004; 89:675-89.

104. Reeves ND, Maganaris CN, Narici MV. Effect of strength training on human patella tendon mechanical properties of older individuals. J Physiol. 2003;548:971-81.

105. Kent-Braun JA, Alexander VNg, Young K. Skeletal muscle contractile and noncontractile components in young and older women and men. J Appl Physiol. 2000;88:662-8.

106. Jubrias SA, Esselman PC, Price LB, Cress ME, Conley KE. Large energetic adaptations of elderly muscle to resistance and endurance training. J Appl Physiol. 2002;92:1663-70.

107. Melov S, Tarnopolsky MA, Beckman K, Felkey K, Hubbard A. Resistance exercise reverses aging in human skeletal muscle. PloS ONE. 2007;2:e465.

108. Psilander N, Damsgaard R, Pilegaard H. Resistance exercise alters MRF and IGF-I mRNA content in human skeletal muscle. J Appl Physiol. 2003;95:1038-44.

109. Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. Expression of IGF-I splice veriants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547:247-54.

110. Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, et al. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscle of elderly men. J Physiol. 2004;555:231-40.

111. Bickel CS, Slade J, Mahoney E, Haddad F, Dudley GA, Adams GR. Time course of molecular responses of human skeletal muscle to acute bouts of resistance exercise. J Appl Physiol. 2005;98:482-8.

112. Blottner D, Salanova M, Pütmann B, Schiffl G, Felsenberg D, Buehring B, et al. Human skeletal muscle structure and function preserved by vibration muscle exercise following 55 days of bed rest. Eur J Appl Physiol. 2006; 97:261-71.

113. Cardinale M, Rittweger J. Vibration exercise makes your muscles and bones stronger: fact or fiction? J Br Menopause Soc. 2006;12:12-8.

114. Cardinale M, Leiper J, Farajian P, Heer M. Whole-body vibration can reduce calciuria induced by hing protein intakes and may counteract bone resorption: A preliminary studi. J Sports Sci. 2007;25:111-9.

115. Bogaerts A, Delecluse C, Claessens AL, Coudyzer W, Boonen S, Verschueren SM. Impact of whole-body vibration training versus fitness training on muscle strenght and muscle mass in older men: a 1-year randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2007;62:630-5.

116. Cardinale M, Lim J. The acute effects of two different whole body vibration frequencies on vertical jump performance. Med Sports. 2003;56:287-92.

117. Cardinale M, Wakeling J. Whole body vibration exercise: are vibrations good for you? Br J Sports Med. 2005;39:585-9.

118. Van Cutsem M, Duchateau J, Haimaut K. Changes in single motor unit hehavior contribuye to the increase in contraction Speedy alter dynamic training in human. J Physiol. 1998;15-513(pt1):295-305.

119. Häkkinen K, Alen M, Kallinen M, Newton RU, Kraemer WJ. Neuromuscular adapotation Turing prolongad strength training, detraining and restrength training in middle-aged and elderly people. Eur J Appl Physiol. 2000;83:51-62.

120. Häkkinen K, Kraemer WJ, Newton RU, Alen M. Changes in electromyographis activity, muscle fibre and force production characteristics during heavy resistance/power strength training in middle-aged and older men and women. Acta Physiolo Scand. 2001a;171:51-62.

121. Häkkinen K, Pakarinen A, Kraemer WJ, Hakkinen A, Valkeinen H, Alen M. Selective muscle hypertrophy, changes in EMG and force and serum hormones during strength training in older women. J Appl Physiol. 2001b; 91:569-80.

122. Vandervoort AA. Aging of the human neuromuscular system. Muscle Nerve. 2002;76:17-25.

123. Clark BC, Manini TM. Functional consequences of sarcopenia and dynapenia in the elderly. Curr Opin Clin Nutr Metab Care. 2010;13:271-6.
124. McCarthy JJ, Esser KA. Anabolic and catabolic pathways regulating skeletal muscle mass. Curr Opin Clin Nutr Metab Care. 2010;13:230-5.
125. D'Antona G, Nisoli E. mTOR signaling as a target of amino acid treatment of the age-related sarcopenia. Interdiscip Top Gerontol. 2010;37:115-41.
126. Paturi S, Gutta AK, Katta A, Kakarla SK, Arvapalli RK, Gadde MK, et al. Effects of aging and gender on muscle mass and regulation of Akt-mTOR-p70s6k related signaling in the F344BN rat model. Mech Ageing Develop. 2010;131:202-9.
127. Drummond MJ, Dreyer HC, Pennings B, Fry CS, Dhanani S, Dillon EL, et al. Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. J Appl Physiol. 2008;104:1452-61.
128. Wu M, Katta A, Gadde MK, Liu H, Kakarla SK, Fannin J, et al. Aging-associated dysfunction of Akt/protein kinase B: S-nitrosylation and acetaminophen intervention. PloS ONE. 2009;4:e6430.
129. Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia. 2009;52:1889-98.
130. Fujita S, Rasmussen BB, Cadenas JG, Drummond MJ, Glynn EL, Sattler FR, et al. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of rapamycin signaling. Diabetes. 2007;56:1615-22.
131. Lopez-Lluch G, Hunt N, Jones B, Zhu M, Jamieson H, Hilmer S, et al. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci USA. 2006;103:1768-73.
132. Hiona A, Sanz A, Kujoth GC, Pamplona R, Seo AY, Hofer T, et al. Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PloS ONE. 2010;5:e11468.
133. Safdar A, Bourgeois JM, Ogborn DI, Little JP, Hettinga BP, Akhtar M, et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci USA. 2011;108:4135-40.
134. Lopez-Lluch G, Irusta PM, Navas P, De Cabo R. Mitochondrial biogenesis and healthy aging. Exp Gerontol. 2008;43:813-9.
135. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem. 2010;47:69-84.
136. Lee HY, Choi CS, Birkenfeld AL, Alves TC, Jornayvaz FR, Jurczak MJ, et al. Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metabol. 2010;12:668-74.
137. Viña J, Gomez-Cabrera MC, Borras C, Froio T, Sanchis-Gomar F, Martinez-Bello VE, et al. Mitochondrial biogenesis in exercise and in ageing. Adv Drug Deliv Rev. 2009;61:1369-74.
138. Konopka AR, Douglass MD, Kaminsky LA, Jemiolo B, Trappe TA, Trappe S, et al. Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J Gerontol. 2010;65:1201-7.
139. Little JP, Safdar A, Wilkin GP, Tarnopolsky MA, Gibala MJ. A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol. 2010;588(Pt 6):1011-22.
140. Gurd BJ, Perry CG, Heigenhauser GJ, Spriet LL, Bonen A. High-intensity interval training increases SIRT1 activity in human skeletal muscle. Appl Physiol Nutr Metab. 2010;35:350-7.
141. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-42.
142. Giresi PG, Stevenson EJ, Theilhaber J, Koncarevic A, Parkington J, Fielding RA, et al. Identification of a molecular signature of sarcopenia. Physiol Genomics. 2005;21:253-63.
143. Zheng B, Ohkawa S, Li H, Roberts-Wilson TK, Price SR. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. 2010;24:2660-9.
144. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399-412.
145. Brault JJ, Jespersen JG, Goldberg AL. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem. 2010;285:19460-71.
146. Geng T, Li P, Yin X, Yan Z. PGC-1alpha promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac Cachexia in mice. Am J Pathol. 2011;178:1738-48.
147. Pasiakos SM, McClung HL, McClung JP, Urso ML, Pikosky MA, Cloutier GJ, et al. Molecular responses to moderate endurance exercise in skeletal muscle. Int J Sport Nutr Exerc Metab. 2010;20:282-90.
148. Verdijk LB, Snijders T, Beelen M, Savelberg HH, Meijer K, Kuipers H, et al. Characteristics of muscle fibre type are predictive of skeletal muscle mass and strenght in elderly men. J Am Geriatr Soc. 2010;58:2069-75.
149. Pöllänen E, Spilä S, Alen M, Ronkainen PH, Ankarberg-Lindgren C, Puolakka J, et al. Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and postmenopausal women. Aging Cell. 2011;10:650-60.